➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Colorcon
Johnson and Johnson
Boehringer Ingelheim
McKinsey
Express Scripts

Last Updated: August 10, 2020

DrugPatentWatch Database Preview

Atenolol - Generic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What are the generic drug sources for atenolol and what is the scope of freedom to operate?

Atenolol is the generic ingredient in five branded drugs marketed by Astrazeneca, Able, Alvogen, Apothecon, Aurobindo Pharma, Dava Pharms Inc, Hlthcare, Invatech, Ipca Labs Ltd, Mylan, Northstar Hlthcare, Nostrum Labs, Pliva, SCS, Sun Pharm Inds Inc, Sun Pharm Industries, Teva, Teva Pharms, Unichem Labs Ltd, Unique Pharm Labs, Watson Labs, Watson Labs Teva, Zydus Pharms Usa, and Zydus Pharms, and is included in forty-two NDAs. Additional information is available in the individual branded drug profile pages.

There are thirty-four drug master file entries for atenolol. Thirty-seven suppliers are listed for this compound.

Drug Prices for atenolol

See drug prices for atenolol

Drug Sales Revenue Trends for atenolol

See drug sales revenues for atenolol

Recent Clinical Trials for atenolol

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Onassis Cardiac Surgery CentreN/A
Massachusetts Eye and Ear InfirmaryPhase 2
Centro Universitario de Ciencias de la Salud, MexicoPhase 4

See all atenolol clinical trials

Pharmacology for atenolol
Paragraph IV (Patent) Challenges for ATENOLOL
Tradename Dosage Ingredient NDA Submissiondate
TENORMIN TABLET;ORAL atenolol 018240

US Patents and Regulatory Information for atenolol

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Alvogen ATENOLOL atenolol TABLET;ORAL 072304-002 Jul 31, 1992 AB RX No No   Start Trial   Start Trial   Start Trial
Zydus Pharms Usa ATENOLOL atenolol TABLET;ORAL 076900-001 Jan 28, 2005 AB RX No No   Start Trial   Start Trial   Start Trial
Teva Pharms ATENOLOL atenolol TABLET;ORAL 074120-001 Feb 24, 1995 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for atenolol

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Alvogen TENORMIN atenolol TABLET;ORAL 018240-002 Approved Prior to Jan 1, 1982   Start Trial   Start Trial
Alvogen TENORMIN atenolol TABLET;ORAL 018240-004 Apr 9, 1990   Start Trial   Start Trial
Alvogen TENORMIN atenolol TABLET;ORAL 018240-002 Approved Prior to Jan 1, 1982   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Johnson and Johnson
Boehringer Ingelheim
Baxter
Express Scripts
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.